LigaChem Biosciences리가켐바이오

Predicted impact: Low· Actual: +4.5% vs sector, volume 1.0× normal (5 trading days)

First patient dosing in Phase 1/2 trial already reported in recent days.

Predicted impact: Low· Actual: +4.5% vs sector, volume 1.0× normal (5 trading days)

Same ADC first-dosing news as item 4; share move already reflected, lowered level.

Predicted impact: Low· Actual: +4.5% vs sector, volume 1.0× normal (5 trading days)

Same first global trial dosing news; repeat of item 4 with share reaction noted.

Predicted impact: Medium· Actual: +4.5% vs sector, volume 1.0× normal (5 trading days)

First US patient dosing of an ADC drug candidate; clinical milestone that can move biotech shares.

Predicted impact: Low· Actual: +4.5% vs sector, volume 1.0× normal (5 trading days)

Award and vague mention of technology transfer talks; no deal size given.